Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Operating Leases (2019 - 2022)

Aytu Biopharma has reported Operating Leases over the past 4 years, most recently at $2.4 million for Q1 2022.

  • Quarterly Operating Leases fell 31.26% to $2.4 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Mar 2022, down 31.26% year-over-year, with the annual reading at $2.6 million for FY2021, 261.93% up from the prior year.
  • Operating Leases was $2.4 million for Q1 2022 at Aytu Biopharma, down from $2.7 million in the prior quarter.
  • Over five years, Operating Leases peaked at $3.5 million in Q1 2021 and troughed at $211056.0 in Q4 2020.
  • The 4-year median for Operating Leases is $804393.0 (2020), against an average of $1.5 million.
  • Year-over-year, Operating Leases plummeted 43.72% in 2020 and then skyrocketed 1186.86% in 2021.
  • A 4-year view of Operating Leases shows it stood at $375000.0 in 2019, then plummeted by 43.72% to $211056.0 in 2020, then skyrocketed by 1186.86% to $2.7 million in 2021, then fell by 11.41% to $2.4 million in 2022.
  • Per Business Quant, the three most recent readings for AYTU's Operating Leases are $2.4 million (Q1 2022), $2.7 million (Q4 2021), and $2.8 million (Q3 2021).